Pfizer OSD Site in KAEC Changes Hands to Jamjoom Pharma

Jamjoom Pharma's agreement to acquire Pfizer's oral solid dosage manufacturing facility in King Abdullah Economic City signals a broader shift in how multinational originators are managing legacy site portfolios across the MEA region, and how regional manufacturers are moving to absorb that capacity. For plant heads and QA directors watching supply chain consolidation in the Gulf, the transition of an established GMP-compliant OSD site carries direct implications for quality system continuity and regional batch release infrastructure.

The facility, located in KAEC, Saudi Arabia, specializes in the manufacture and packaging of oral solid dosage pharmaceutical products and operates across the full production chain, supported by on-site quality control laboratories. The site will be integrated into Jamjoom Pharma's existing manufacturing network, which the company states is intended to enhance production and operational capabilities. The transaction remains subject to customary conditions precedent, including regulatory approvals, and Jamjoom Pharma has committed to disclosing material developments in accordance with applicable regulatory requirements.

From a quality systems perspective, the handover of a Pfizer-operated site introduces the standard challenges of any facility divestiture: aligning incumbent quality management frameworks with the acquiring organization's ICH Q10-based pharmaceutical quality system, managing site master file transitions, and maintaining uninterrupted sterility assurance and process validation documentation through change of ownership. Workforce continuity is also a stated priority, with Jamjoom Pharma indicating commitment to stability and capability development for the existing site workforce.

Strategic context: The acquisition supports Saudi Arabia's localization agenda for pharmaceutical manufacturing and aligns with Vision 2030 industrial development priorities. Jamjoom Pharma has framed the move as part of a long-term platform to strengthen regional supply resilience and expand access to medicines across the Middle East and Africa. CEO Tarek Hosni described the agreement as "an important milestone in our growth journey," citing the goal of building "a scalable platform that supports sustainable growth while maintaining the highest standards of quality and operational excellence."

Source: Jamjoom Pharma press release via EIN Presswire, April 28, 2026.